ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
US approves joint damage data for Cosentyx
pharmatimes
June 21, 2018US regulators have approved new evidence showing that Novartis’ Cosentyx significantly slows progression of joint structural damage in patients with active psoriatic arthritis (PsA).
Pharma Sources Insight January 2025
